Trial NCT01887522

View at ClinicalTrials.gov 
Org. Study IDs: 2012-003005-10
Secondary IDs: 022 2012/1883

Last trial update was posted on 2022-05-31

MeSH Interventions

Nilotinib Vinblastine

MeSH Conditions

Glioma

Other Conditions

Recurrent Low-grade Gliomas Refractory Low-grade Gliomas

Stopping Reasons

the results of the interim analysis are clear with a significant advantage in terms of PFS in favor of the control arm (Vinblastine alone) over the investigational arm (Vinblastine + Nilotinib).

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID